Becton Dickinson and Co stock (US0758871091): Drops 2.4% to $143.97 after earnings

Becton Dickinson and Co (BDX) shares fell 2.4% to $143.97 on May 13, 2026, following quarterly earnings release on May 7. The medical technology firm reported results amid a year-to-date decline of 25.8%.

Becton Dickinson and Co stock declined 2.4% to close at $143.97 on May 13, 2026, on the NYSE, after extended trading showed a 2.45% rebound to $147.50, MarketBeat as of 05/13/2026. The move follows the company's quarterly earnings on May 7, 2026, with shares down 25.8% year-to-date from $194.11 on January 1, 2026. Trading volume reached 3.83 million shares versus an average of 3.33 million.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Becton, Dickinson and Company
• Sector/industry: Medical - Dental Supplies
• Headquarters/country: United States
• Core markets: Healthcare institutions, life sciences, pharmaceuticals
• Key revenue drivers: Medical devices, instrument systems, reagents
• Home exchange/listing venue: NYSE (BDX)
• Trading currency: USD

Becton Dickinson and Co: core business model

Becton Dickinson and Co develops, manufactures and sells medical devices, instrument systems and reagents worldwide. The company serves healthcare institutions, physicians, life science researchers, clinical laboratories and the pharmaceutical industry. With 72,000 employees since its founding in 1897, it holds a market capitalization of $39.67 billion as of May 13, 2026, MarketBeat as of 05/13/2026.

Main revenue and product drivers for Becton Dickinson and Co

Annual sales reached $21.84 billion for the reported period, per company data published with recent financials. Key products include medical supplies, diagnostic tools and laboratory equipment. The firm maintains a dividend yield of 2.92% and a P/E ratio of 36.45, reflecting its position in the health care equipment sub-industry.

Conclusion

Becton Dickinson and Co faces pressure after recent earnings and a sharp year-to-date drop, with shares showing volatility in extended trading. The medical technology leader continues to generate substantial revenue from its core offerings amid a stable dividend profile. US investors track its NYSE-listed performance for exposure to healthcare equipment trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.